Skip to main content

Table 5 End points at Month 19

From: Impact of patient education on chronic heart failure in primary care (ETIC): a cluster randomised trial

 

Intervention (n = 69)

Control (n = 82)

P-value

Primary outcomes

 SF-36 mental health score, mean (SD)

58 (22.1)

58.7 (23.9)

0.57

 SF-36 physical health score, mean (SD)

52.8 (23.8)

51.6 (25.5)

0.58

 MLHFQ score, mean (SD)

33.4 (22.1)

27.2 (23.3)

0.74

Secondary outcomes

 NYHA stage, n (%)a

  I

14 (22.6)

21 (29.2)

 

  II

35 (56.5)

34 (47.2)

0.73

  III

12 (19.3)

15 (20.8)

 

  IV

1 (1.6)

2 (2.8)

 

 BMI kg/m2, n (%)b

   < 25

13 (22)

29 (40.3)

 

  25–30

25 (42.4)

33 (45.8)

0.007

   ≥ 30

21 (35.6)

10 (13.9)

 

 Patient adherencec, n (%)

  Good adherence

23 (37.1)

32 (42.1)

 

  Minor nonadherence

35 (56.5)

42 (55.3)

0.55

  Nonadherence

4 (6.4)

2 (2.6)

 

Mortality, n (%)

10/115 (8.7)

15/126 (11.9)

0.41

Total CHF decompensation/visits (%)

65/470 (13.8)

93/545 (17.1)

0.16

Hospitalisation for CHF decompensation/visits (%)

18/65 (27.7)

22/93 (23.7)

0.57

Hospitalisation not for CHF decompensation/visits (%)

50/470 (10.6)

59/545 (10.8)

0.92

Hospitalisation/visits (%)

62/470 (13.2)

74/545 (13.6)

0.86

Hospitalisation/patients (%)

41/115 (35.7)

54/126 (42.9)

0.26

Total number of days of hospitalisation

1037

867

 

HF hospitalisation/patients (%)

13/115 (11.3)

17/126 (13.5)

0.61

Death or hospitalisation/patients (%)

45/115 (39.1)

60/126 (47.6)

0.18

Death or HF hospitalisation/patients (%)

20/115 (17.3)

28/126 (22.2)

0.35

dTotal visits related to GP/patients (%)

90/115 (78 %)

106/126(84 %)

0.24

dNumber of GP visits/patient, mean (SD)

8.1 (5.3)

6.4 (4.5)

0.02

Total visits related to cardiologist/patients (%)

85/115 (74 %)

84/126 (67 %)

0.22

Number of cardiologist visits/patient, mean (SD)

3.1 (2.2)

3.1 (2)

0.92

  1. a n = 17 missing data for New York Heart Association stage
  2. b n = 20 missing data for body mass index
  3. c n = 13 missing data for adherence
  4. dAdditional general practitioner visits (in addition to those dedicated to the study)
  5. Significant P-value are in bold